title: Gene therapy prospects--intranasal delivery of therapeutic genes.
abstract: Gene therapy is recognized to be a novel method for the treatment of various disorders. Gene therapy strategies involve gene manipulation on broad biological processes responsible for the spreading of diseases. Cancer, monogenic diseases, vascular and infectious diseases are the main targets of gene therapy. In order to obtain valuable experimental and clinical results, sufficient gene transfer methods are required. Therapeutic genes can be administered into target tissues via gene carriers commonly defined as vectors. The retroviral, adenoviral and adeno-associated virus based vectors are most frequently used in the clinic. So far, gene preparations may be administered directly into target organs or by intravenous, intramuscular, intratumor or intranasal injections. It is common knowledge that the number of gene therapy clinical trials has rapidly increased. However, some limitations such as transfection efficiency and stable and long-term gene expression are still not resolved. Consequently, great effort is focused on the evaluation of new strategies of gene delivery. There are many expectations associated with intranasal delivery of gene preparations for the treatment of diseases. Intranasal delivery of therapeutic genes is regarded as one of the most promising forms of pulmonary gene therapy research. Gene therapy based on inhalation of gene preparations offers an alternative way for the treatment of patients suffering from such lung diseases as cystic fibrosis, alpha-1-antitrypsin defect, or cancer. Experimental and first clinical trials based on plasmid vectors or recombinant viruses have revealed that gene preparations can effectively deliver therapeutic or marker genes to the cells of the respiratory tract. The noninvasive intranasal delivery of gene preparations or conventional drugs seems to be very encouraging, although basic scientific research still has to continue.
authors.affiliation: Department of Cell Biology, Cancer Center, Warsaw, Poland.
authors.forename: Karolina
authors.initials: K
authors.lastname: Podolska
authors.forename: Anna
authors.initials: A
authors.lastname: Stachurska
authors.forename: Karolina
authors.initials: K
authors.lastname: Hajdukiewicz
authors.forename: Maciej
authors.initials: M
authors.lastname: Małecki
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000281:Administration, Intranasal; D003550:Cystic Fibrosis / Q000628:therapy; D000229:Dependovirus / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D008175:Lung Neoplasms / Q000628:therapy; D019896:alpha 1-Antitrypsin Deficiency / Q000628:therapy